van der Gaast et al developed a simple prognostic model for predicting survival in a patient with an undifferentiated carcinoma arising from an unknown primary site. The authors are from University Hospital Rotterdam-Dijkzigt and Erasmus University in Rotterdam.
Parameters:
(1) WHO (or ECOG performance scale)
(2) ratio of serum alkaline phosphatase to the upper limit of normal
ratio of serum alkaline phosphatase =
= (serum alkaline phosphatase) / (upper limit of normal reference range)
WHO Performance |
Serum Alkaline Phosphatase Ratio |
Prognostic Group |
0 |
< 1.25 |
good |
>= 1 |
< 1.25 |
fair |
0 |
>= 1.25 |
fair |
>= 1 |
>= 1.25 |
poor |
Prognostic Group |
Median Survival |
Probability of 4 Year Survival |
good |
> 4 years |
52% |
fair |
10 months |
15% |
poor |
4 months |
0% (0% at 14 months) |
Purpose: To evaluate a patient with an undifferentiated carcinoma of unknown primary site using the prognostic model of van der Gaast et al.
Specialty: Hematology Oncology, Surgery, general
Objective: severity, prognosis, stage
ICD-10: C80,